SG healthtech startup Mesh Bio eyes PH expansion after raising $3.5m

Founded in 2018 by Andrew Wu and Arsen Batagov, Mesh Bio is a digital health startup focused on addressing the growing global clinical burden of metabolic diseases due to an aging population and challenges in care delivery.

Mesh Bio, a Singapore-based health deep tech startup, is looking at scaling the deployment of its predictive analytics solutions to the Philippines after raising $3.5 million in a Series A funding round.

The plan is to offer the company’s digital twin technologies to healthcare providers and scale the deployment of these solutions across Hong Kong and Southeast Asia, mainly Indonesia and the Philippines.

Founded in 2018 by Andrew Wu and Arsen Batagov, Mesh Bio is a digital health startup focused on addressing the growing global clinical burden of metabolic diseases due to an aging population and challenges in care delivery.  

The funding round was anchored by Southeast Asia-focused sector-agnostic venture capital firm East Ventures and backed by Elev8, Seeds Capital, and other existing shareholders.

“We are excited to announce the closure of our Series A funding, this pivotal step empowers us to expand our digital health solutions for chronic disease management in Southeast Asia,” said Wu, the startup’s co-founder and chief executive officer.

The new investment comes three months after Mesh Bio secured historic regulatory approval and an implementation pilot with public health systems for one of its digital twin technologies in Singapore, which represents a major opportunity to improve patient outcomes from chronic diseases.

In October 2023, it received approval from Singapore’s Health Sciences Authority (HSA) to market its HealthVector® Diabetes as a Software Medical Device (SaMD).

A report cited by Mesh Bio showed that the high prevalence of chronic diseases from diabetes to heart disease in Southeast Asia has pushed more general practitioners who lack specialist training in endocrinology, to manage patients with chronic diseases.

In the Philippines, the burden of both diseases is high. The prevalence of diabetes, a chronic, metabolic disorder characterized by hyperglycemia, is about 7.1% in adults between 20-79 years old in 2019.

The startup said its solutions offer patient data and predictive analytics that equip doctors with information and intelligence about their patients and the diseases they live with.  

“Southeast Asia presents myriad unmet healthcare needs, and our focus is to address these gaps effectively,” Wu added.

Christian Francisco

START A DISCUSSION

Do you have any questions or insights regarding this article?
The most frequently mentioned topics will be placed in our discussion board.

Registration isn't required

Subscribe
Notify of
guest

0 Comments
Oldest
Newest Most Voted